Skip to main content


Log in

New aspect of anti-inflammatory action of lipo-prostaglandinE1 in the management of collagen diseases-related skin ulcer

  • Original Article
  • Published:
Rheumatology International Aims and scope Submit manuscript


It is considered that the mechanism in intractable cutaneous ulcer is deeply associated with prolongation at the inflammatory phase. Having evaluated the effects of Lipo-prostaglandin E1 (Lipo-PGE1) with indicators such as the reduction ratio of the ulcer area and the values of the inflammatory markers after dividing them into two groups of collagen diseases and non-collagen diseases and giving them Lipo-PGE1, we managed to obtain the result that Lipo-PGE1 administration could influence various inflammatory markers such as C-reactive protein (CRP), IL-6, and VEGF in addition to reduction of the ulcer region. It also suggested that Lipo-PGE1 has the effect of maintaining an appropriate balance of induction of inflammation and angiogenesis. Additionally, it revealed that Lipo-PGE1 controls the production of cytokines, which are associated with the growth of collagen diseases. From these results, it can be expected that Lipo-PGE1 will act favorably on intractable collagen diseases.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others


  1. Yamaguchi Y, Yoshikawa K (2001) Cutaneous wound healing: an update. J Dermatol 28:521–534

    PubMed  CAS  Google Scholar 

  2. Cianfarani F, Tommasi R, Failla CM, Viviano MT, Annessi G, Papi M, Zambruno G, Odorisio T (2006) Granulocyte/macrophage colony-stimulating factor treatment of human chronic ulcers promotes angiogenesis associated with de novo vascular endtherial growth factor transcription in the ulcer bed. Br J Dermatol 154:34–41

    Article  PubMed  CAS  Google Scholar 

  3. Lauer G, Sollberg S, Colo M, Flamme I, Sturzebecher J, Mann K, Krieg T, Eming SA (2000) Expression and proteolysis of vascular endtherial growth factor is increased in chronic wounds. J Invest Dermatol 115:12–18

    Article  PubMed  CAS  Google Scholar 

  4. Papps PJ, Fallek SR, Gracia A, Anaki CT, Back TL, Duran WK, Hobson RW 2nd (1995) Role of leukocyte activation in patients with venous stasis ulcers. J Surg Res 59:553–559

    Article  Google Scholar 

  5. Frenkel O, Shani E, Ben-Bassat I, Brok-Simoni F, Rozenfeld-Granot G, Kajakaro G, Rechavi G, Amariglio N, Shinar E, Danon D (2002) Activated macrophages for treating skin ulceration:gene expression in human monocytes after hypo-osmotic shock. Clin Exp Immunol 128:59–66

    Article  PubMed  CAS  Google Scholar 

  6. Ganter U, Arcone R, Toniatti C, Morrone G, Ciliberto G (1989) Dual contorol of C-reactive protein gene expression by interleukin-1 and interleukin-6. EMBO J 8:3773–3779

    PubMed  CAS  Google Scholar 

  7. Rothlein R, Mainolfi EA, Czajkowski M, Marlin SD (1991) A form of circulating ICAM-1 in human serum. J Immunol 147:3788–3793

    PubMed  CAS  Google Scholar 

  8. Hahn J, Junger M, Friedrich B, Zuder D, Steins A, Hahn M, Klyscz T (1997) Cutaneous inflammation limited to the region of the ulcer in chronic venous insufficiency. Vasa 26:277–281

    PubMed  CAS  Google Scholar 

  9. Rowe IF, Deans AC (1986) Serum C-reactive protein measurement in pyoderma gangreosom. Dermatologica 173:216–219

    PubMed  CAS  Google Scholar 

  10. Heshmat NM, EL-Kerdanv TH (2007) Serum levels of vascular endothrial growth factor in children and adolescents with systemic lupus erythematosus. Pediatr Allergy Immunol 18:346–353

    Article  PubMed  Google Scholar 

  11. Kikuchi K, Kubo M, Kadono T, Yazawa N, Ihn H, Tamaki K (1998) Serum concentrations of vascular endothrial growth factor in collagen diseases. Br J Dermatol 139:1049–1051

    Article  PubMed  CAS  Google Scholar 

  12. Fava RA, Olsen NJ, Spencer-Green G, Yeo KT, Berse B, Jackman RW, Senger DR, Dvorak HF, Brown LF (1994) Vascular permeability factor/endothrial growth factor (VPF/VEGF) accumulation and expression in human synovial fluids and rheumatoid synovial tissue. J Exp Med 180:341–346

    Article  PubMed  CAS  Google Scholar 

  13. Murphy MA, Jovce WP, Condron C, Bouchier-Haves D (2002) A reduction in serum cytokine levels parallels healing of venous ulcers in patients undergoing compression therapy. Eur J Vasc Endovasc Surg 23:349–352

    Article  PubMed  CAS  Google Scholar 

  14. Drinkwater SL, Burnand KG, Ding R, Smith A (2003) Increased but ineffectual angiogenic drive in nonhealing venous leg ulcers. J Vasc Surg. 38:1106–1112

    Article  PubMed  Google Scholar 

  15. Aoki S, Imai K, Yachi A (1993) Soluble intercellular adhesion molecule-1 (ICAM-1) antigen in patients with rheumatoid arthritis. Scand J Immunol 38:485–490

    Article  PubMed  CAS  Google Scholar 

  16. Machold KP, Kiener HP, Graninger W, Graninger WB (1993) Soluble intercellular adhesion molecule-1(ICAM-1) in patients with rheumatoid arthritis and systemic lupus erthmatosus. Clin Immunol Immunopathol 68:74–78

    Article  PubMed  CAS  Google Scholar 

  17. Cush JJ, Rothlein R, Lindslev HB, Mainolfi EA, Lipskv PE (1993) Increased levels of circulating intercellular adhesion molecute 1 in the sera of patients with rheumatoid arthritis. Arthritis Rheum 36:1098–1102

    Article  PubMed  CAS  Google Scholar 

  18. Sfikakis PP, Tesar J, Baraf H, Lipnick R, Klipple G, Tsokos GO (1993) Circulating intercellular adhesion molecute-1 in patients with systemic sclerosis. Clin Immunol Immunopathol 68:88–92

    Article  PubMed  CAS  Google Scholar 

  19. Kiener H, Graninger W, Machold K, Aringer M, Graninger WB (1994) Increased levels of circulating intercellular adhesion molecule-1 in patients with systemic sclerosis. Clin Exp Rheumatol 12:483–487

    PubMed  CAS  Google Scholar 

  20. Murota H, Muroi E, Yamaoka T, Hamasaki Y, Katayama I (2006) Successful treatment with regimen of intravenous gamma globulin and cyclophosphamide for dermatomyositis accompanied by interstitial pneumonia, opportunistic infection and steroid psychosis. Allergol Int 55:199–202

    Article  PubMed  Google Scholar 

  21. Mizushima Y, Yanagawa A, Hoshi A (1983) Prostaglandin E1 is more effective, when incorporated in lipid microspheres, for treatment of peripheral vascular diseases in man. J Pharm Pharmacol 35:666–667

    PubMed  CAS  Google Scholar 

  22. Tsutsui K, Shirasaki F, Takata M, Takehara K (1996) Successful treatment of livedo vasculitis with beraprost sodium: a possible mechanism of thrombomodulin upregulation. Dermatology 192:120–124

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Hiroyuki Murota.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Murota, H., Kotobuki, Y., Umegaki, N. et al. New aspect of anti-inflammatory action of lipo-prostaglandinE1 in the management of collagen diseases-related skin ulcer. Rheumatol Int 28, 1127–1135 (2008).

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: